263 related articles for article (PubMed ID: 26833657)
21. Timing of basiliximab induction and development of acute rejection in lung transplant patients.
Swarup R; Allenspach LL; Nemeh HW; Stagner LD; Betensley AD
J Heart Lung Transplant; 2011 Nov; 30(11):1228-35. PubMed ID: 21764603
[TBL] [Abstract][Full Text] [Related]
22. Effects of prophylactic use of sirolimus on bronchiolitis obliterans syndrome development in lung transplant recipients.
Sacher VY; Fertel D; Srivastava K; Panos A; Nguyen D; Baxter T; Shafazand S; Pham SM
Ann Thorac Surg; 2014 Jan; 97(1):268-74. PubMed ID: 24119986
[TBL] [Abstract][Full Text] [Related]
23. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data.
Cai J; Terasaki PI
Transplantation; 2010 Dec; 90(12):1511-5. PubMed ID: 21057388
[TBL] [Abstract][Full Text] [Related]
24. Everolimus Versus Mycophenolate Mofetil De Novo After Lung Transplantation: A Prospective, Randomized, Open-Label Trial.
Strueber M; Warnecke G; Fuge J; Simon AR; Zhang R; Welte T; Haverich A; Gottlieb J
Am J Transplant; 2016 Nov; 16(11):3171-3180. PubMed ID: 27104933
[TBL] [Abstract][Full Text] [Related]
25. Is transplant operation important in determining posttransplant risk of bronchiolitis obliterans syndrome in lung transplant recipients?
Hadjiliadis D; Davis RD; Palmer SM
Chest; 2002 Oct; 122(4):1168-75. PubMed ID: 12377838
[TBL] [Abstract][Full Text] [Related]
26. Cytolytic Induction Therapy Improves Clinical Outcomes in African-American Kidney Transplant Recipients.
Taber DJ; McGillicuddy JW; Bratton CF; Rohan VS; Nadig S; Dubay D; Baliga PK
Ann Surg; 2017 Sep; 266(3):450-456. PubMed ID: 28654544
[TBL] [Abstract][Full Text] [Related]
27. Comparing Outcomes between Antibody Induction Therapies in Kidney Transplantation.
Koyawala N; Silber JH; Rosenbaum PR; Wang W; Hill AS; Reiter JG; Niknam BA; Even-Shoshan O; Bloom RD; Sawinski D; Nazarian S; Trofe-Clark J; Lim MA; Schold JD; Reese PP
J Am Soc Nephrol; 2017 Jul; 28(7):2188-2200. PubMed ID: 28320767
[TBL] [Abstract][Full Text] [Related]
28. Immediate postoperative inflammatory response predicts long-term outcome in lung-transplant recipients.
Hall DJ; Baz M; Daniels MJ; Staples ED; Klodell CT; Moldawer LL; Beaver TM
Interact Cardiovasc Thorac Surg; 2012 Oct; 15(4):603-7. PubMed ID: 22815323
[TBL] [Abstract][Full Text] [Related]
29. Induction Strategies in Lung Transplantation: Alemtuzumab vs. Basiliximab a Single-Center Experience.
Furukawa M; Chan EG; Ryan JP; Hyzny EJ; Sacha LM; Coster JN; Pilewski JM; Lendermon EA; Kilaru SD; McDyer JF; Sanchez PG
Front Immunol; 2022; 13():864545. PubMed ID: 35720296
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and outcome of bronchiolitis obliterans syndrome after lung transplantation. Washington University Lung Transplant Group.
Sundaresan S; Trulock EP; Mohanakumar T; Cooper JD; Patterson GA
Ann Thorac Surg; 1995 Nov; 60(5):1341-6; discussion 1346-7. PubMed ID: 8526624
[TBL] [Abstract][Full Text] [Related]
31. Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study.
Jaksch P; Ankersmit J; Scheed A; Kocher A; Muraközy G; Klepetko W; Lang G
Am J Transplant; 2014 Aug; 14(8):1839-45. PubMed ID: 25039364
[TBL] [Abstract][Full Text] [Related]
32. Are heart-lung transplant recipients protected from developing bronchiolitis obliterans syndrome?
Moffatt-Bruce SD; Karamichalis J; Robbins RC; Whyte RI; Theodore J; Reitz BA
Ann Thorac Surg; 2006 Jan; 81(1):286-91; discussion 291. PubMed ID: 16368382
[TBL] [Abstract][Full Text] [Related]
33. An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation.
Cherukuri A; Salama AD; Carter C; Smalle N; McCurtin R; Hewitt EW; Hernandez-Fuentes M; Clark B; Baker RJ
Am J Transplant; 2012 Apr; 12(4):919-31. PubMed ID: 22390816
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of Alemtuzumab Versus Basiliximab Induction: A Retrospective Cohort Study in Lung Transplant Recipients.
Whited LK; Latran MJ; Hashmi ZA; Wang IW; Wozniak TC; Duncan MD; Roe DW; Baz MA; Hage CA
Transplantation; 2015 Oct; 99(10):2190-5. PubMed ID: 25769073
[TBL] [Abstract][Full Text] [Related]
35. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results.
Kaufman DB; Leventhal JR; Axelrod D; Gallon LG; Parker MA; Stuart FP
Am J Transplant; 2005 Oct; 5(10):2539-48. PubMed ID: 16162205
[TBL] [Abstract][Full Text] [Related]
36. Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents.
Whitson BA; Kilic A; Lehman A; Wehr A; Hasan A; Haas G; Hayes D; Sai-Sudhakar CB; Higgins RS
Clin Transplant; 2015 Jan; 29(1):9-17. PubMed ID: 25284138
[TBL] [Abstract][Full Text] [Related]
37. Blood CD9
Brosseau C; Danger R; Durand M; Durand E; Foureau A; Lacoste P; Tissot A; Roux A; Reynaud-Gaubert M; Kessler R; Mussot S; Dromer C; Brugière O; Mornex JF; Guillemain R; Claustre J; Magnan A; Brouard S;
Am J Transplant; 2019 Nov; 19(11):3162-3175. PubMed ID: 31305014
[TBL] [Abstract][Full Text] [Related]
38. To induce or not to induce: a 21st century evaluation of lung transplant immunosuppression's effect on survival.
Whitson BA; Lehman A; Wehr A; Hayes D; Kirkby S; Pope-Harman A; Kilic A; Higgins RS
Clin Transplant; 2014 Apr; 28(4):450-61. PubMed ID: 24750290
[TBL] [Abstract][Full Text] [Related]
39. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome.
Kesiraju S; Paritala P; Rao Ch UM; Athmakuri SM; Reddy VS; Sahariah S
Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):9-15. PubMed ID: 24434376
[TBL] [Abstract][Full Text] [Related]
40. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
